
Search
Selected Filter
Filter Results
Displaying 231–240 of 304 research results
-
May 5, 2016
ARVO 2016: High-School Sophomore Finds Gene Mutation in Family with Choroideremia
Aditya A. Guru, 16, used whole exome sequencing (WES), an innovative genetic-screening technology, to find the mutation.
-
May 4, 2016
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
In August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
May 3, 2016
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
There are innumerable considerations for researchers developing therapies.
-
May 2, 2016
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
When the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Apr 28, 2016
ARVO 2016: Choroideremia Gene Therapy in Clinical Trial Continues to Perform Well
Five of six patients in NightStaRx’s choroideremia gene-therapy trial continue to benefit from the treatment.
-
Mar 17, 2016
Two New Videos Highlight the Foundation's Vital Role in Retinal Research
Dr. Shannon Boye and her Foundation-funded research is the subject of not just one but two new Foundation videos.
-
Dec 22, 2015
Retinal Researchers May Be Looking for You
If you have a heritable retinal disease, consider registering with My Retina Tracker, the Foundation’s free, secure and confidential registry for people with inherited retinal diseases.
-
Nov 11, 2015
Past Sun Exposure Increases AMD Risk
Researchers from the University of Cologne in Germany and Radboud University in the Netherlands found that increased sunlight exposure during working life significantly increases risk of AMD later in life.
-
Oct 8, 2015
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
Aug 4, 2015
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.